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Tissue transglutaminase is a calcium-dependent enzyme that catalyzes the cross-linking of
polypeptide chains, including those of extracellular matrix (ECM) proteins, through the
formation of epsilon-(gamma-glutamyl) lysine bonds. This crosslinking leads to the
formation of protein polymers that are highly resistant to degradation. As a consequence,
the enzyme has been implicated in the deposition of ECM protein in fibrotic diseases such
as pulmonary fibrosis and atherosclerosis. In this study, we have investigated the
involvement of tissue transglutaminase in the development of kidney fibrosis in adult male
Wistar rats submitted to subtotal nephrectomy (SNx). Groups of six rats were killed on days
7, 30, 90, and 120 after SNx. As previously described, these rats developed progressive
glomerulosclerosis and tubulo-interstitial fibrosis. The tissue level of epsilon-(gamma-
glutamyl) lysine cross-link (as determined by exhaustive proteolytic digestion followed by
cation exchange chromatography) increased from 3.47+/- 0.94 (mean+/-SEM) in controls to
13.24+/-1.43 nmol/g protein 90 d after SNx, P </= 0.01. Levels of epsilon-(gamma-glutamyl)
lysine cross-link correlated well with the renal fibrosis score throughout the 120 observation
days (r = 0.78, P </= 0.01). Tissue homogenates showed no significant change in overall
transglutaminase activity (14C putrescine incorporation assay) unless adjusted for the loss
of viable tubule cells, when an increase from 5.77+/-0.35 to 13.93+/-4.21 U/mg DNA in
cytosolic tissue transglutaminase activity was seen. This increase was supported […]
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Abstract
 
Tissue transglutaminase is a calcium-dependent enzyme
that catalyzes the cross-linking of polypeptide chains, includ-
ing those of extracellular matrix (ECM) proteins, through
the formation of 
 
e
 
-(
 
g
 
-glutamyl) lysine bonds. This cross-
linking leads to the formation of protein polymers that are
highly resistant to degradation. As a consequence, the en-
zyme has been implicated in the deposition of ECM protein
in fibrotic diseases such as pulmonary fibrosis and athero-
sclerosis.
In this study, we have investigated the involvement of tis-
sue transglutaminase in the development of kidney fibrosis
in adult male Wistar rats submitted to subtotal nephrec-
tomy (SNx). Groups of six rats were killed on days 7, 30, 90,
and 120 after SNx. As previously described, these rats devel-
oped progressive glomerulosclerosis and tubulo-interstitial
fibrosis. The tissue level of 
 
e
 
-(
 
g
 
-glutamyl) lysine cross-link
(as determined by exhaustive proteolytic digestion followed
by cation exchange chromatography) increased from 3.47
 
6
 
0.94 (mean
 
6
 
SEM) in controls to 13.24
 
6
 
1.43 nmol/g protein
90 d after SNx, 
 
P
 
 
 
# 
 
0.01. Levels of 
 
e
 
-(
 
g
 
-glutamyl) lysine
cross-link correlated well with the renal fibrosis score
throughout the 120 observation days (
 
r
 
 
 
5
 
 0.78, 
 
P
 
 
 
# 
 
0.01).
Tissue homogenates showed no significant change in overall
transglutaminase activity (
 
14
 
C putrescine incorporation as-
say) unless adjusted for the loss of viable tubule cells, when
an increase from 5.77
 
6
 
0.35 to 13.93
 
6
 
4.21 U/mg DNA in
cytosolic tissue transglutaminase activity was seen. This in-
crease was supported by Western blot analysis, showing a
parallel increase in renal tissue transglutaminase content.
Immunohistochemistry demonstrated that this large increase
in 
 
e
 
-(
 
g
 
-glutamyl) lysine cross-link and tissue transglutami-
nase took place predominantly in the cytoplasm of tubular
cells, while immunofluorescence also showed low levels of
the 
 
e
 
-(
 
g
 
-glutamyl) lysine cross-link in the extracellular renal
interstitial space.
The number of cells showing increases in tissue transglu-
taminase and its cross-link product, 
 
e
 
-(
 
g
 
-glutamyl) lysine
appeared greater than those showing signs of typical apop-
tosis as determined by in situ end-labeling. This observed
association between tissue transglutaminase, 
 
e
 
-(
 
g
 
-glutamyl)
lysine cross-link, and renal tubulointerstitial scarring in rats
submitted to SNx suggests that tissue transglutaminase may
play an important role in the development of experimental
renal fibrosis and the associated loss of tubule integrity. (
 
J.
Clin. Invest. 
 
1997. 99:2950–2960.)
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Introduction
 
The progression of chronic renal insufficiency is characterized
by a relentless fibrosis of the kidney. Both increased synthesis
and decreased breakdown of the renal extracellular matrix
(ECM)
 
1
 
 have been implicated (1, 2). The latter may be due to
changes in the ECM-regulating enzymes, including a fall in re-
nal metalloproteinases, or an increase in their inhibitors (tissue
inhibitors of metalloproteinases and plasminogen activator in-
hibitors) (3, 4). Another factor in the pathogenesis of renal fi-
brosis may be the resistance of the deposited ECM to break-
down. This resistance has been put forward as a contributing
factor in the development of other fibrogenic processes, in-
cluding lung fibrosis and atherosclerosis (5–8). Tissue trans-
glutaminase–induced cross-linking of the ECM may underlie
its resistance to breakdown.
Transglutaminases (E.C.2.3.2.13) are calcium-dependent
enzymes which catalyze the posttranslation modification of
proteins through an acyl transfer reaction between the 
 
g
 
 car-
boxamide group of a peptide-bound glutaminyl residue and
various primary amines (9). Covalent cross-links using 
 
e
 
-(
 
g
 
-
glutamyl) lysine bonds are stable and resistant to enzymatic,
chemical, and mechanical disruption (9). Endopeptidases ca-
pable of hydrolyzing the 
 
e
 
-(
 
g
 
-glutamyl) lysine cross-links
formed by transglutaminases have not been described in verte-
brates, and even lysosomes do not contain enzymes capable of
splitting the 
 
e
 
-(
 
g
 
-glutamyl) lysine bonds (10–12). A number
of transglutaminase enzymes have been characterized which
have distinct genes, structures, and physiological functions. Ex-
amples include the plasma Factor XIIIa involved in cross-linking
fibrin during wound healing (13), and the keratinocyte trans-
glutaminase involved in the formation of the cornified enve-
lope during terminal differentiation (14, 15). A further trans-
glutaminase, the tissue transglutaminase, is the most widespread
member of this family, and is present in many different cell
types.
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Recent evidence suggests that the tissue transglutaminase
may have a number of key roles in cells. These include a role in
programmed cell death (16–18), cell adhesion (19), and inter-
actions between the cell and its ECM via the cross-linking of
proteins such as fibronectin, laminin, nidogen, and collagens
types I, III, and IV (7, 20, 21). In addition, tissue transglutami-
nase has been demonstrated recently to play a role in the cova-
lent stabilization of collagen fibrillar formation through cross-
linking of the core fibrils (22). Involvement in ECM diseases
has also been noted (5), as raised tissue transglutaminase lev-
els have been detected in paraquat-induced pulmonary fibro-
sis. Since then, transglutaminase has been ascribed roles in ath-
erosclerosis (6–8), cataract formation (23), and neurofibrillary
tangles in Alzheimer’s disease (24) and tau-containing poly-
mers (25).
In view of the possible role of tissue transglutaminase in
diseases characterized by perturbations in cell death and ECM
metabolism, we have designed this study to investigate the role
of tissue transglutaminase in renal fibrosis induced in rats by
subtotal nephrectomy. We aimed to determine whether the ex-
pression of the enzyme was raised in scarred kidneys, to local-
ize its expression, and to detect changes in its cross-link product.
 
Methods
 
Experimental animals and protocol
 
Male Wistar rats (Sheffield University strain) of approximately simi-
lar weight (350–400 g) and age (8–10 wk) were subjected to subtotal
(5/6th) nephrectomy (SNx) by complete removal of the left kidney
and upper and lower pole resections of the right kidney. Rats were
housed 2–4 to a cage and maintained at 20
 
8
 
C and 45% humidity on a
12-h light/dark cycle. They were allowed free access to standard rat
chow (Labsure Ltd., Cambridge, United Kingdom) and tap water. At
days 7, 30, 90, and 120 after SNx, experimental groups of six rats were
killed, and the remnant kidneys were removed. At each time point,
four control animals were also killed that had been subjected to surgi-
cal manipulation of the kidneys at the time of the nephrectomy. Age-
and weight-matched spontaneously hypertensive rats (
 
n
 
 
 
5
 
 8) were
also studied to control for systemic hypertension. Before death, all
rats had their renal function (serum creatinine and creatinine clear-
ance), proteinuria, and systolic blood pressure measured. Creatinine
was measured by standard autoanalyzer technique, proteinuria by the
Biuret method, and blood pressure by tail-cuff plethysmography. All
procedures were carried out under license according to regulations
laid down by Her Majesty’s Government, United Kingdom (Animals
Scientific Procedures Act, 1986).
 
Assessment of renal scarring
 
Analysis of renal scarring was determined on formol calcium-fixed,
paraffin-embedded sections (4 
 
m
 
m) stained by hematoxylin and eosin
(H & E) or Masson’s trichrome. One of the authors (A. Meguid El
Nahas) scored the severity of glomerulosclerosis and tubulo-intersti-
tial scarring, blinded to their code, according to a previously de-
scribed arbitrary score (from 1 to 4) (26). Scores were attributed as
follows: glomerulosclerosis score (1–4): 1 
 
5
 
 normal glomeruli; 2 
 
5
 
presence of mild segmental glomerulosclerosis affecting 
 
,
 
 25% of
the glomerular tuft; 3 
 
5
 
 moderate segmental sclerosis affecting 25–
50% of the tuft, 4 
 
5
 
 diffuse severe glomerulosclerosis affecting 
 
.
 
 50%
of the tuft including glomeruli with total tuft obliteration, fibrosis,
and obsolescence (see Fig. 1, 
 
bottom
 
). A minimum of 25 glomeruli
per kidney/remnant kidney was examined, and the mean of the glom-
erular scores was taken to represent the severity of glomerulosclero-
sis for a given rat.
Tubulointerstitial scarring was scored as follows: (1–4): 1 
 
5
 
 nor-
mal tubules and interstitium; 2 
 
5
 
 mild tubular atrophy and interstitial
fibrosis; 3 
 
5
 
 moderate tubular atrophy and dilatation with marked in-
terstitial fibrosis; 4 
 
5
 
 end-stage kidney with extensive interstitial fi-
brosis and few remaining atrophic tubules (see Fig. 1, 
 
top
 
). A score
was given to each microscopic field viewed at a magnification of 200.
A minimum of 10 fields was scored per kidney/remnant kidney, and
the mean value was taken to represent the tubulointerstitial score for
a given rat.
To express biochemical measurements in relation to the amount
of residual renal tissue within remnant kidneys, the amount of tubular
tissue was determined using both volume and numerical density
methods (27). Determination of tubular cell volume was made using a
25-point lattice projected onto an H & E–stained section. The percent
volume of tubule cells was calculated by dividing the number of
points overlying tubule cells by the total number of points. Estima-
tion of tubule cell number was made by numerical density calcula-
tions. Tubule nuclei were counted on H & E–stained sections in 10
light microscopic fields (
 
3
 
200) of predetermined area. Calculation of
tubule cell number per kidney was made assuming a nuclei diameter
of 6 
 
m
 
m and a density of 1 g/cm
 
3
 
 in control and diseased tissue.
When determining the amount of tubular tissue remaining (when
calculated as a percentage of the control at each time point after ne-
phrectomy), there was no statistical difference between the volume
density and numerical density methods. Tubular tissue correction cal-
culations were made using the numerical density values.
 
Measurement of tissue transglutaminase
 
Antigen.
 
Levels of transglutaminase antigen were determined by im-
munoprobing of Western blots. Tissue homogenates were separated
on a 10% (wt/vol) polyacrylamide denaturing gel using the method of
Laemmli (28), and then electroblotted (Immun-Lite PVDF mem-
branes; Biorad Laboratories, Herfordshire, United Kingdom). The
Western blot was then probed with a polyclonal goat anti–guinea pig
liver transglutaminase (TCS Biologicals, United Kingdom). Primary
antibody binding was revealed using an anti–goat alkaline phos-
phatase (Vector Laboratories Ltd., Peterborough, United Kingdom)
and the Immun-Lite chemiluminescent detection system (Biorad) at
25
 
8
 
C.
 
Activity.
 
Transglutaminase activity was measured by the Ca
 
2
 
1
 
-
dependent incorporation of [1,4,-
 
14
 
C]putrescine into 
 
N
 
9
 
,
 
N
 
9
 
-dimethyl-
casein as described previously (29). Briefly, tissue homogenates were
incubated for 20 min at 37
 
8
 
C with [1,4,-
 
14
 
C]putrescine (2.5 mM, 3.97
mCi/mmol; Amersham International, Little Chalfont, United King-
dom), dithiothreitol (3.8 mM), calcium chloride (2.5 mM), and di-
methylcasein (5 mg/ml). A sample of the homogenate was then
spotted onto 3-mm filter paper and precipitated with ice-cold 10%
(wt/vol) TCA. After washing, the amount of putrescine incorporation
into precipitated protein was determined by scintillation counting.
Values were then corrected for DNA content. 1 U of activity is equiv-
alent to 1 nmol of putrescine incorporated per hour at 37
 
8
 
C.
 
Distribution of tissue transglutaminase and 
 
e
 
-(
 
g
 
-glutamyl) 
lysine cross-link
 
The distribution of immunoreactive transglutaminase and its cross-
link, 
 
e
 
-(
 
g
 
-glutamyl) lysine present in proteins, was determined by im-
munohistochemistry and immunofluorescence.
For immunohistochemistry, 4-
 
m
 
m sections were cut from formol
calcium-fixed paraffin-embedded tissue. These sections were depar-
affinized using xylene, rehydrated, and endogenous peroxidase activ-
ity was quenched with 3% (vol/vol) hydrogen peroxide in phosphate-
buffered saline (PBS). Antigen was further revealed by proteinase K
digestion for 7.5 min (20 
 
m
 
g/ml) at room temperature. Sections were
then blocked with appropriate blocking serum (filtered 20% [vol/vol]
nonimmune serum in PBS for 20 min at room temperature), and the
primary antibody (monoclonal anti–guinea pig liver transglutaminase
[Cub7402]) (30) at 1:200 dilution, polyclonal rabbit anti–rat liver
transglutaminase at 1:100 dilution, monoclonal anti–
 
e
 
-(
 
g
 
-glutamyl)
lysine (31) at 1:20 dilution (kind gift of G. Quash and S. El-Alaoui,
Laboratoire d’Immunochimie, Faculte de Medecine Lyon-Sud, France)
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applied overnight at 4
 
8
 
C. The monoclonal anti–
 
e
 
-(
 
g
 
-glutamyl) lysine
antibody (No. 15D
 
4
 
H
 
5
 
) showed no cross-reactivity to conjugated
polyamines, acetylated polyamines, or to acetylated lysine. Primary anti-
body was revealed using the relevant peroxidase-conjugated second-
ary antibody (Dako, United Kingdom) at 1:500 dilution and staining
for peroxidase activity using 3-amino-9-ethylcarbazole or 3,3
 
9
 
-diami-
nobenzidine tetrachloride (Sigma Chemical Co., Poole, United King-
dom). Sections were then counterstained with Mayers hematoxylin
for 5 min before mounting.
For immunofluorescence studies, 4 
 
m
 
m formol calcium-fixed,
paraffin-embedded sections were treated as described above (but
omitting the quenching step for endogenous peroxidase) using the
monoclonal anti–guinea pig liver antibody (Cub 7402) or the anti–
 
e
 
-(
 
g
 
-glutamyl) lysine antibody (15D
 
4
 
H
 
5
 
). A fluorescein conjugated
anti–mouse secondary antibody (Dako) was then used at a dilution of
1:100. Sections were counterstained in propidium iodide (Sigma) and
mounted in Vectorshield (Vector Laboratories).
 
Quantitation of 
 
e
 
-(
 
g
 
-glutamyl) lysine
 
Transverse sections of kidney of 
 
z 
 
100 mg wet wt (taken from either
above or below the papilla region) were used for the measurement of
 
9
 
N
 
-
 
e
 
-(
 
g
 
-glutamyl) lysine isopeptide content. After removal of lipids,
cell proteins were subjected to sequential exhaustive proteolytic di-
gestion over several days using subtilisin, pronase E, leucine ami-
nopeptidase, prolidase, and carboxypeptidase Y (Sigma). Prepurifica-
tion of dipeptide from interfering amino acids was undertaken by
cation exchange chromatography (100 
 
3
 
 10 mm Dowex-50 
 
3
 
 4–400)
column as previously described (17). Analysis of the 
 
e
 
-(
 
g
 
-glutamyl;
Pharmacia LKB Biotechnology, Hertfordshire, United Kingdom)
lysine dipeptide was undertaken by cation exchange chromatography
using an LKB 4151–amino acid analyzer by a modification of that
previously described using lithium citrate buffers (32). Separation of
the dipeptide was achieved on a stainless steel 5 
 
3
 
 250 mm column
containing Ultrapac 8 cation exchange resin (8
 
6
 
0.5 
 
m
 
m-particle size;
Pharmacia LKB Biotechnology, Hertfordshire, United Kingdom) us-
ing a constant temperature of 25
 
8
 
C and a stepwise gradient of increas-
ing molarity and changing pH of lithium citrate buffers as described
previously (32). The program of elution involved 9 min of 0.2 M
lithium citrate buffer, pH 2.8, 23 min of 0.3 M lithium citrate buffer,
pH 3.0, and 63.5 min of 0.6 M lithium citrate buffer, pH 2.6, at a flow
rate of 25 ml/h. Detection of the dipeptide which eluted around 88
min was achieved using postcolumn derivatization with 
 
s
 
-pthalalde-
hyde/2,
 
b
 
-mercaptoethanol at a flow rate of 20 ml/h which was ana-
lyzed in a fluorescent detector (LS1, Perkin-Elmer Corp., Beacons-
field, UK) (340 nm excitation, 450 nm emission). Data acquisition was
by means of an interface box (900 series; Nelson Analytical, Cuper-
tino, CA). Chromatograms were stored, compared, and analyzed us-
ing an IBM compatible computer and software (model 2600, version
5; Nelson Analytical). The amount of 
 
e
 
-(
 
g
 
-glutamyl) lysine in each
sample was quantified by standard addition of 
 
e
 
-(
 
g
 
-glutamyl) lysine
dipeptide as previously described (32). 
 
e
 
-(
 
g
 
-glutamyl) lysine is ex-
Figure 1. Massons Trichrome staining of kidney sections demonstrating the scarring index measurements scale from 1 to 4. (Top), Tubule scar-
ring; (bottom), glomerular scarring.
Transglutaminase and Kidney Fibrosis 2953
pressed as nanomoles per gram of protein. Sample protein was deter-
mined both before and after the subtilisin digestion using the DC pro-
tein assay system (Biorad) as per manufacturer’s instructions.
Detection of apoptosis
This relied on in situ end-labeling using a modification of the Apop-
Tag™ system (Oncor Inc., Gaithersburg, MD). Tissue was fixed in for-
mol calcium overnight, and was embedded in paraffin. 5-mm sections
were deparaffinized using xylene, rehydrated, and the tissue was di-
gested with 20 mg/ml proteinase K for 15 min at room temperature.
Endogenous peroxidase activity was quenched with 2% (vol/vol) hy-
drogen peroxide for 5 min. Application of terminal transferase en-
zyme in equilibration buffer containing dUTP labeled with digoxige-
nin, and binding of the anti–digoxigenin peroxidase–conjugated
antibody was performed as per manufacturer’s instructions. 3-amino-
9-ethylcarbazole substrate was applied to reveal end-labeling sites,
and was incubated at room temperature for up to 30 min. The section
was then counterstained with Mayers hematoxylin for 5 min at room
temperature.
This technique provides a method of identifying cells undergoing
apoptosis by the ability of the terminal transferase enzyme to attach
digoxigenin-labeled nucleotides to chromatin fragmented in the early
stages of the apoptotic program.
Statistical analysis
Results are given as mean6standard error of the mean (M6SEM).
Differences between groups were determined by one-way analysis of
variance (ANOVA). Correlations between variables were deter-
mined by linear regression analysis. Probability of , 5% was taken as
significant.
Results
General observations. SNx rats demonstrated a steady increase
in proteinuria and serum creatinine with time (Table I), indi-
cating progressive renal insufficiency. Systolic blood pressure
was significantly raised in SNx rats from day 7 onward, and
was comparable on days 90 and 120 to that of SHRs (Table I).
All rats survived the subtotal nephrectomy and the experi-
mental time course. The level of kidney fibrosis rose steadily
throughout the experimental time course, showing severe scar-
ring (Fig. 1, 3 and 4) by day 90 after SNx. Tubular and glomer-
ular scarring indices were comparable at each time point (r 5
0.97, P # 0.01). While proteinuria showed a strong correlation
with overall renal scarring (r 5 0.79, P # 0.01), the reciprocal
of serum creatinine demonstrated a weak correlation with
scarring (r 5 0.49, P # 0.05).
Immunohistochemistry. In control kidneys, the immuno-
histochemistry revealed a very low background staining for
both transglutaminase and e-(g-glutamyl) lysine cross-link that
was predominantly intracellular, and in the main restricted to
tubule cells. In SNx kidneys, there was a visible rise in both
transglutaminase and its product throughout the time course.
This rise was almost exclusively intracellular, and was confined
to the tubule cells. The staining for both of these reached a
maximum between days 90 and 120 (Fig. 2, A–D). In most
cases, cells that appeared to give intense staining for e-(g-
glutamyl) lysine cross-link still demonstrated intact nuclei. A
quantitative analysis of these changes over the time course of
the experiment is described in the biochemical assessment of
transglutaminase and e-(g-glutamyl) lysine cross-link.
Although the immunohistochemistry demonstrated a pri-
marily intracellular location for both transglutaminase and the
e-(g-glutamyl) lysine cross-link, a low level of stain for cross-link
was occasionally observed in the interstitial space surrounding
the tubules in late-stage SNx animals (data not shown) that
was not found in controls. The more sensitive immunofluores-
Table I. Serum Creatinine, Proteinuria, Systolic Blood Pressure, Body Weight, Scarring Index, and Percentage of Control Tubule 
Mass at Death (Mean6SEM) in Control, Hypertensive, and SNx Animals (Time Course)
Days after SNx Body weight
Serum
creatinine
Systolic blood
pressure Proteinuria Scarring index
% Normal tubule mass
remaining
g mmol/liter mmHg mg/24 h
7 d
SNx (n 5 6) 294.1866.12 74.265.67‡ 150.467.31* 49.863.36* 1.5360.08 (T) 86
1.5560.08 (G)
Sham (n 5 4) (343.1614.85) (32.6762.44) (139.260.74) (26.561.05) — —
30 d
SNx (n 5 6) 332613.06 79.3566.77‡ 164.664.43* 93.965.73‡ 2.6360.13 (T) 52
2.4860.12 (G)
Sham (n 5 4) — — — — — —
90 d
SNx (n 5 6) 404.5626.25 89.7165.51‡ 176.1762.91* 256.266.45‡ 3.2260.36 (T) 31
3.2960.25 (G)
Sham (n 5 4) (440616.60) (32.1161.18) (142.761.43) (36.764.60) — —
SHR (n 5 4) 404.567.60 33.862.1 18965.9 49.863.35 — 96
120 d
SNx (n 5 6) 390.7621.55 308.7620.21‡ 17562.88* 19467.48‡ 3.0760.38 (T) 42
3.0960.37 (G)
Sham (n 5 4) (500628.40) (33.463.1) (150.468.96) (27.8462.15) — —
SHR (n 5 4) 46469.17 31.7561.70 19567.07‡ 56.466.15 — 94
The numbers in parentheses refer to sham-operated animals. T, tubular; G, glomerular. *P # 0.05 compared to respective sham; ‡P # 0.01 compared
to respective sham.
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cence, while still demonstrating the majority of e-(g-glutamyl)
lysine cross-link in SNx tissue to be intracellular, clearly shows
e-(g-glutamyl) lysine cross-link associated with the ECM in the
peritubular fibrotic lesions (Fig. 2, E and F).
There was also a strong staining for both transglutaminase
and e-(g-glutamyl) lysine cross-link in what appeared to be cel-
lular fragments found in a number of tubule lumen in heavily
scarred kidneys. These detached fragments displayed a mor-
phology that could be described as similar to an apoptotic
body (Fig. 2, B and G).
Transglutaminase levels. Tissue levels of transglutaminase
as measured by activity (data not shown) initially showed a
slight, but not significant, decrease in transglutaminase levels
when normalized for either protein or DNA in the nephrecto-
mized animals compared to controls. When this decrease was
corrected for the number of surviving tubule cells (that ap-
peared to be the prime transglutaminase-expressing cells as
shown by immunohistochemistry) (Table I), then a threefold
increase was seen at 90 d (P # 0.05), rising to fivefold by day
120 (P # 0.01) (Fig. 3). Transglutaminase antigen levels deter-
mined by Western blot analysis of tissue homogenates (Fig. 4)
also showed an increase when adjusted for tubule cell number.
This increase demonstrated a fivefold increase by day 90 after
nephrectomy (P # 0.01), rising to eightfold by day 120 (P #
0.01) (Fig. 5). A weak positive correlation was noted between
tubule-adjusted tissue transglutaminase levels and the severity
of tubulointerstitial fibrosis (r 5 0.46, P 5 0.08).
Estimation of e-(g-glutamyl) lysine. The level of e-(g-glu-
tamyl) lysine cross-link in control animals (as assessed by cation
exchange chromatography of proteolytically digested samples)
remained constant throughout the experimental period,
whereas a fivefold increase in tissue levels was detected by day
90 in the SNx animals (3.4760.94 to 13.2461.43 nmol/g pro-
tein, P # 0.01). When these figures are corrected for the num-
ber of tubule cells within the tissue, then a 29-fold increase in
e-(g-glutamyl) lysine cross-link is observed in the SNx animals
compared to controls at 120 d (P # 0.01) (Fig. 6). This in-
crease in e-(g-glutamyl) lysine is in agreement with the findings
from immunohistochemistry, demonstrating a good correla-
tion between transglutaminase antigen levels and its e-(g-glu-
tamyl) lysine product (r 5 0.76, P # 0.025). Furthermore, a
good correlation was observed between tubulointerstitial scar-
ring and levels of tubule cell number adjusted e-(g-glutamyl)
lysine cross-links at each time point in the experimental series
(Fig. 7), with a strong correlation between individual animal
levels of tubule cell number–adjusted e-(g-glutamyl) lysine cross-
links and the severity of tubulointerstitial scarring (Fig. 8, r 5
0.86, P # 0.01). In addition, the glomerular scarring index also
showed a high correlation with levels of e-(g-glutamyl) lysine
cross-link (r 5 0.89, P # 0.01).
In situ end-labeling as a measure of cellular apoptosis. In situ
end-labeling (ApopTag™) was used as an assessment of the de-
gree of apoptosis in this study. Fig. 2 H shows a typical Apop-
Tag™-staining of a cell in apoptosis. This cell demonstrates
condensed chromatin that is being pinched off into an apop-
totic body, while a neighboring cell is phagocytozing an apop-
totic body. Visual comparison of a severely scarred kidney
stained for either transglutaminase or e-(g-glutamyl) lysine
cross-link (Fig. 2, B and D) with in situ end-labeling (Fig. 2 I)
demonstrates that cells showing DNA cleavage tend to be dis-
crete cells within a few tubules, whereas increased trans-
glutaminase and e-(g-glutamyl) lysine cross-links typically af-
fect the entire tubule, with the majority of tubular cells within
a damaged area showing staining. Fig. 2 clearly demonstrates
the large differences between cells expressing DNA cleavage
and transglutaminase in typical fields from scarred kidney. It
cannot, however, be ruled out that cells showing increased lev-
els of intracellular e-(g-glutamyl) lysine cross-links have under-
Figure 2. Representative sections from normal and scarred kidneys at day 90 after SNx. A, B, and G are stained for tissue transglutaminase, C 
and D are stained for e-(g-glutamyl) lysine cross-link using immunohistochemistry. E and F are stained for e-(g-glutamyl) lysine using an immu-
nofluorescence stain. A, C, and E are sections from control kidneys, while B, D, and F are from scarred kidneys. H and I are sections from a 
scarred kidney that has been in situ end-labeled with a digoxigenin-labeled nucleotide (apoptosis).
Figure 3. Transglutaminase activity mea-
surement from control/hypertensive (SHR) 
(shaded bars), and SNx (black bars) animals 
as determined by a [14C]putrescine incor-
poration into N9,N9-dimethyl casein assay. 
Data represent mean transglutaminase ac-
tivity (U/mg DNA) adjusted for tubule cell 
number6SEM from four or more animals.
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gone cleavage of their DNA into large fragments (33) which
would not be detected by the techniques used in this study.
Discussion
In this study, we have investigated tissue transglutaminase pro-
tein levels in experimental renal fibrosis by both activity and
antigen measurements, and have determined the enzyme
product, the e-(g-glutamyl) lysine dipeptide cross-link. We
have also localized both transglutaminase and e-(g-glutamyl)
lysine by immunohistochemistry and immunofluorescence. In
addition, as transglutaminase is one of the few known effector
elements of apoptosis, or programmed cell death, we have in-
vestigated if changes in transglutaminase expression are a con-
sequence of variations in apoptosis as detected by in situ end-
labeling techniques.
The data presented clearly show an increase in trans-
glutaminase-mediated protein cross-linking with renal disease
progression. This increase in e-(g-glutamyl) lysine cross-link
detected both immunohistochemically and by cation exchange
chromatography of digested samples, indicates that the tissue
transglutaminase observed predominantly in renal tubules is
functionally active. The in situ end-labeling data coupled with
light microscopy morphology demonstrate that the increase in
both the enzyme and its product is not a consequence of the in-
duction of apoptosis. Cleavage of DNA into larger fragments,
(33) however, or activation of interleukin-converting enzymes
(ICE) like serine proteases (34) cannot be ruled out since im-
munohistochemical methods to detect this type of damage are
still unavailable. Immunohistochemical investigations revealed
that the increases in transglutaminase and e-(g-glutamyl) ly-
sine were seen exclusively in tubule cells, and that this increase
was predominantly intracellular. Immunofluorescence, how-
ever, showed that detectable levels of e-(g-glutamyl) lysine
cross-links were also present in the peritubular extracellular
matrix in remnant kidneys, although these levels were usually
in the late stages of the disease process. Although the increase
in e-(g-glutamyl) lysine cross-links is most likely to result from
the increases in tissue transglutaminase, it cannot be ruled out
that such an increase in e-(g-glutamyl) lysine cross-links may
also be because of the activation of Factor XIIIa during the in-
flux of plasma into the damaged areas.
We noted a strong correlation between tubulointerstitial
scarring and e-(g-glutamyl) lysine cross-link levels suggesting a
causal association. The higher correlation shown between re-
nal scarring and e-(g-glutamyl) lysine cross-link levels when
compared to the correlation of renal scarring with tissue trans-
glutaminase levels is not surprising, as a small transient rise in
tissue transglutaminase expression or activation of the residual
transglutaminase present in tubular cells would be expected to
lead to large and cumulative increases in e-(g-glutamyl) lysine
cross-link products over several months.
Increased e-(g-glutamyl) lysine levels correlate well with
both tubulo-interstitial and glomerular scarring, yet we can
only detect raised transglutaminase and e-(g-glutamyl) lysine
Figure 4. Western blot of kidney homogenates from control and SNx 
animals immunoprobed with a polyclonal anti–guinea pig liver trans-
glutaminase as described in Methods.
Figure 5. Densitometric analysis of the 
Western blot in Fig. 3 showing control/hy-
pertensive (SHR) animals (shaded bars) 
and SNx animals (black bars). Data repre-
sent mean density (arbitrary units) ad-
justed for tubule cell number6SEM from 
four animals.
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in tubule cells. This observation lends itself to the inference
that tissue transglutaminase may not play a role in glomerular
scarring, which is not unusual since the mechanisms of scarring
of the two structures are diverse, and tubular cells (unlike
those of the glomeruli) are rich sources of enzymes. The close
correlation between glomerular and tubular scarring, however,
does not preclude causal interactions whereby the trans-
glutaminase-mediated cross-linking of tubular cells, and the as-
sociated tubulointerstitial fibrosis, may contribute to the scle-
rosis of the glomeruli (35). Finally, it cannot be excluded that
there is a failure to attach or inaccessibility of antibodies to the
insoluble material of the glomerular basement membrane. For
instance, tissue transglutaminase’s tight association with fi-
bronectin (36), and the fact that tissue transglutaminase is also
a substrate for its own catalytic action (which results in the en-
zyme being cross-linked into the matrix), makes immunochem-
ical antigen detection difficult.
Our data indicate a good degree of correlation between in-
creased tissue transglutaminase expression and e-(g-glutamyl)
lysine cross-link. Although we could not demonstrate that the
increased enzyme levels precede the accumulation of its cross-
link product, the specificity of the transglutaminase enzymatic
reaction suggests a causal association between the enzyme ac-
tivity and its product. The lack of a strong correlation between
renal transglutaminase content and scarring is to be expected,
as small effective enzyme changes over prolonged periods can
lead to disproportionate increases in the nondegradable e-(g-
glutamyl) lysine cross-link product. Thus, correlation between
the product and not enzyme levels provides a more accurate
determination of the enzyme’s effects.
Most hypotheses relating to the pathogenesis of renal fi-
brosis have focused on the increased synthesis of the ECM (1,
2) or its decreased breakdown (3, 4). Little attention has been
paid to qualitative changes in renal ECM preventing its break-
down. If the ECM was deposited in such a way as to reduce the
ability of proteases to degrade it, possibly by covalent stabili-
Figure 6. e-(g-glutamyl) lysine cross-link 
measurements adjusted for surviving tu-
bule cell number for control/hypertensive 
(SHR) (shaded bars) and SNx animals 
(black bars) as determined by exhaustive 
proteolytic digestion and cation exchange 
chromatography as described in Methods. 
Data represent mean cross-link values 
(nmol/g protein)6SEM from four or more 
animals.
Figure 7. Level of renal scar-
ring in SNx animals as deter-
mined by pathological morphol-
ogy assessment compared with 
SNx e-(g-glutamyl) lysine levels. 
Data represent mean values6 
SEM from four or more animals.
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zation of the fibrils by incorporation of e-(g-glutamyl) lysine
cross-links (22) that could potentially inhibit the action of spe-
cific collagenases required before general endopeptidase deg-
radation (37), then this stabilization would move the deposi-
tion-degradation balance towards accumulation and fibrosis.
This mechanism may be the case if ECM polymers were
formed with a high proportion of bonds resistant to proteolytic
degradation, such as e-(g-glutamyl) lysine bonds formed by
transglutaminase (9). Such a mechanism has been postulated
to explain the fibrotic process taking place within the walls of
atherosclerotic vessels where the cross-linking of matrix
proteins is increased (6–8). The process also is similar to the
cross-linking of fibrin by Factor XIII, which makes the cross-
linked fibrin much more resistant to plasmin. The presence of
transglutaminase and its product in scarred renal tubules
would therefore support this hypothesis. To explain the pre-
dominantly intracellular localization of the tissue transglutami-
nase enzyme to the contrasting dual location (intracellular/ex-
tracellular) of its cross-linked product, it is tempting to
speculate that these enzymes cross-link the ECM intra-
cellularly, as it is produced by tubular cells before its extracel-
lular deposition. It cannot be excluded, however, that small
amounts of transglutaminase, undetectable by immunohis-
tochemistry, are released from the basolateral aspect of tubu-
lar cells in response to tissue injury, and contribute to the ex-
tracellular cross-linking of ECM proteins. Although tissue
transglutaminase is essentially an intracellular enzyme (it has
no leader sequence or evidence for protein glycosylation), there
is good evidence to indicate transglutaminase activity in the
extracellular environment (38) where its involvement in matrix
assembly and basement membrane stabilization is well de-
scribed (7, 21, 22, 39, 40). The mechanism of its release from
cells into the extracellular environment, however, is still to be
elucidated.
The association between tubular tissue transglutaminase
and renal fibrosis may also involve transforming growth factor-b
(TGF-b). Transglutaminase has been shown to play a key role
in the activation of latent TGF-b1 (38), while TGF-b1 can in
turn lead to de novo synthesis of tissue transglutaminase (41).
TGF-b1 is one of the major fibrogenic growth factors within
the kidney, and has been implicated in its fibrosis (42). In that
respect, it is interesting to observe that the tubular distribution
of transglutaminase corresponds to that reported for TGF-b
within scarred kidneys (43, 44). Another factor which may fa-
cilitate transglutaminase-induced cross-linking in scarred kid-
neys is the known increase in its putrescine substrate (used in
formation of N9,N9-bis[g-glutamyl]polyamine linkage) within
these kidneys from exogenous sources (45). Thus, the scarred
kidney, and in particular its tubular cells, would provide the
optimal environment for the action of tissue transglutaminase
and the generation of its cross-linked products.
Apoptosis is known to take place within remnant kidneys,
and seems to predominate within tubular cells (46). Tissue
transglutaminase is a known effector enzyme of the cellular
apoptotic process (6, 11). The activation of cellular trans-
glutaminase is thought to lead to the assembly of highly cross-
linked protein shells (apoptotic envelopes) within the dying
cell, which temporarily stabilizes the cell’s integrity before
clearance by phagocytosis, and shedding into body cavities (17,
18). It was therefore important to determine whether the tubu-
lar transglutaminase is associated with apoptotic cells. Our ini-
tial data indicate that there were significantly more tubular
cells expressing tissue transglutaminase and increased e-(g-
glutamyl) lysine cross-link levels when compared to those
showing signs of classical apoptosis as determined by in situ
end-labeling, although it is important to stress the limitations
of detecting apoptosis by this technique. It should be noted,
however, that many cells expressing transglutaminase seem to
have normal-looking nuclei. What we are observing seems to
be a situation where there is a high intracellular tubular tissue
transglutaminase and e-(g-glutamyl) lysine cross-link content
in the absence of the associated DNA cleavage (detectable by
in situ end-labeling) characteristic of apoptosis or well ad-
vanced necrosis.
This tubular response to injury, involving transglutaminase-
mediated cytoplasmic peptide cross-linking, may be an at-
tempt to stabilize the injured tubules and maintain structural
integrity (47–51) before ECM deposition. Such a function
Figure 8. Linear regression cor-
relation of cross-link data with 
tubule scarring index. r 5 0.86, 
P # 0.01.
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would also be comparable to the Factor XIIIa (the plasma
transglutaminase) during wound healing (13, 52). Further-
more, excessive levels of protein cross-linking within a cell are
likely to influence cell function, and consequently viability.
Therefore, it would appear from our data that we are poten-
tially observing a transglutaminase-induced/mediated cell death
in these tubule cells, which may be similar to that taking place
in the formation of terminally differentiated keratinocytes
by keratinocyte transglutaminase (15). Furthermore, tubular
structural and morphological changes similar to the ones we
observed in cross-linked tubular cells have been associated
with the loss of renal function (53). It may be that this mecha-
nism of tubular cell cross-linking is another contributor to the
loss of tubular cell mass in renal scarring along with necrosis
and apoptosis.
At the present stage, we can only speculate as to the under-
lying biochemistry of the progression of renal scarring and the
role of transglutaminase in the fibrotic event, although it is
clear that there are perturbations of transglutaminase and its
major product e-(g-glutamyl) lysine cross-link in this disease.
The observation that these perturbations occur in other fi-
brotic lesions (5–8) would suggest an important role for this
enzyme in this disease. Further studies are necessary, however,
using specific transglutaminase inhibitors, to gain a clear in-
sight as to how transglutaminase is involved in the fibrotic pro-
cess.
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